Cipla Limited (CIPLA) — corporate announcements

All
Important
Financial Update
Fund Raise
Board Meeting
Dividend/Bonus
JV/Acquisition
Investor Meet
Insider Trade
Pledging
Others

Download our app

Get the best experience on mobile

Join 5K+ users on Alpha Tribe

Cipla Limited

$CIPLA

Cipla is engaged in the Business of Pharmaceuticals.(Source : 202003 Annual Report Page No:157)

Pharmaceuticals

03-09-2026 | 08:13 pm

Cipla's US subsidiary partners with Qilu for exclusive licensing & supply of a Keytruda biosimilar (QL2107) in the US market. This strategic move aims to expand Cipla's oncology portfolio and improve access to affordable biologics.

PDF

03-09-2026 | 04:49 pm

Cipla is advancing with the merger of Inzpera Healthsciences. Shareholders and creditors have 30 days to submit any objections to the Tribunal regarding the proposed scheme, which otherwise will be presumed approved.

PDF

02-09-2026 | 08:02 pm

Cipla Limited has informed the Exchange about Newspaper Publication regarding opening of special window for re-lodgement of transfer and dematerialisation of physical shares

PDF

31-08-2026 | 03:53 pm

Cipla secured an exclusive licensing agreement with SBP Group for TQB2102, a promising HER2 bispecific ADC. This boosts Cipla's oncology pipeline for breast cancer patients across India, South Africa, and key emerging markets, enhancing access to innovative therapies.

PDF

28-08-2026 | 09:11 pm

Cipla's subsidiary InvaGen's USFDA inspection at its Central Islip facility is classified as Voluntary Action Indicated (VAI). This signals no immediate regulatory enforcement action, a positive development for operations.

PDF

Download our app

Cipla Limited

Cipla Limited

Press Release

Cipla Limited

General Updates

Cipla Limited

Copy of Newspaper Publication

Cipla Limited

Press Release

Cipla Limited

General Updates